Victoria S Pelak1,2, Asher Mahmood3, Kathryn Abe-Ridgway3. 1. Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA. Victoria.Pelak@CUAnschutz.edu. 2. Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, USA. Victoria.Pelak@CUAnschutz.edu. 3. Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA.
Abstract
PURPOSE OF REVIEW: To provide perspectives on the importance of understanding longitudinal profiles of posterior cortical atrophy (PCA) and report results of a scoping review to identify data and knowledge gaps related to PCA survival and longitudinal clinical and biomarker outcomes. RECENT FINDINGS: Thirteen longitudinal studies were identified; all but two had fewer than 30 participants with PCA. Relatively few longitudinal data exist, particularly for survival. In PCA, posterior cortical dysfunction and atrophy progress at faster rates compared to non-posterior regions, potentially up to a decade after symptom onset. Unlike typical AD, PCA phenotype-defined cognitive dysfunction and atrophy remain relatively more severe compared to other regions throughout the PCA course. Select cognitive tests hold promise as PCA outcome measures and for staging. Further longitudinal investigations are critically needed to enable PCA inclusion in treatment trials and to provide appropriate care to patients and enhance our understanding of the pathophysiology of dementing diseases.
PURPOSE OF REVIEW: To provide perspectives on the importance of understanding longitudinal profiles of posterior cortical atrophy (PCA) and report results of a scoping review to identify data and knowledge gaps related to PCA survival and longitudinal clinical and biomarker outcomes. RECENT FINDINGS: Thirteen longitudinal studies were identified; all but two had fewer than 30 participants with PCA. Relatively few longitudinal data exist, particularly for survival. In PCA, posterior cortical dysfunction and atrophy progress at faster rates compared to non-posterior regions, potentially up to a decade after symptom onset. Unlike typical AD, PCA phenotype-defined cognitive dysfunction and atrophy remain relatively more severe compared to other regions throughout the PCA course. Select cognitive tests hold promise as PCA outcome measures and for staging. Further longitudinal investigations are critically needed to enable PCA inclusion in treatment trials and to provide appropriate care to patients and enhance our understanding of the pathophysiology of dementing diseases.
Authors: Melissa E Murray; Neill R Graff-Radford; Owen A Ross; Ronald C Petersen; Ranjan Duara; Dennis W Dickson Journal: Lancet Neurol Date: 2011-07-27 Impact factor: 44.182
Authors: Micah D J Peters; Christina M Godfrey; Hanan Khalil; Patricia McInerney; Deborah Parker; Cassia Baldini Soares Journal: Int J Evid Based Healthc Date: 2015-09
Authors: Julie S Snowden; Cheryl L Stopford; Camille L Julien; Jennifer C Thompson; Yvonne Davidson; Linda Gibbons; Antonia Pritchard; Corinne L Lendon; Anna M Richardson; Anoop Varma; David Neary; David Mann Journal: Cortex Date: 2007-10 Impact factor: 4.027
Authors: John L Robinson; Hayley Richardson; Sharon X Xie; EunRan Suh; Vivianna M Van Deerlin; Brian Alfaro; Nicholas Loh; Matias Porras-Paniagua; Jeffrey J Nirschl; David Wolk; Virginia M-Y Lee; Edward B Lee; John Q Trojanowski Journal: Brain Date: 2021-04-12 Impact factor: 15.255
Authors: Jonathan M Schott; Sebastian J Crutch; Minerva M Carrasquillo; James Uphill; Tim J Shakespeare; Natalie S Ryan; Keir X Yong; Manja Lehmann; Nilufer Ertekin-Taner; Neill R Graff-Radford; Bradley F Boeve; Melissa E Murray; Qurat Ul Ain Khan; Ronald C Petersen; Dennis W Dickson; David S Knopman; Gil D Rabinovici; Bruce L Miller; Aida Suárez González; Eulogio Gil-Néciga; Julie S Snowden; Jenny Harris; Stuart M Pickering-Brown; Eva Louwersheimer; Wiesje M van der Flier; Philip Scheltens; Yolande A Pijnenburg; Douglas Galasko; Marie Sarazin; Bruno Dubois; Eloi Magnin; Daniela Galimberti; Elio Scarpini; Stefano F Cappa; John R Hodges; Glenda M Halliday; Lauren Bartley; Maria C Carrillo; Jose T Bras; John Hardy; Martin N Rossor; John Collinge; Nick C Fox; Simon Mead Journal: Alzheimers Dement Date: 2016-03-15 Impact factor: 21.566